Mark C. Chandler

480 total citations
7 papers, 382 citations indexed

About

Mark C. Chandler is a scholar working on Psychiatry and Mental health, Surgery and Neurology. According to data from OpenAlex, Mark C. Chandler has authored 7 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Psychiatry and Mental health, 1 paper in Surgery and 1 paper in Neurology. Recurrent topics in Mark C. Chandler's work include Acute Myeloid Leukemia Research (1 paper), Cancer Genomics and Diagnostics (1 paper) and Cardiac Arrest and Resuscitation (1 paper). Mark C. Chandler is often cited by papers focused on Acute Myeloid Leukemia Research (1 paper), Cancer Genomics and Diagnostics (1 paper) and Cardiac Arrest and Resuscitation (1 paper). Mark C. Chandler collaborates with scholars based in United States. Mark C. Chandler's co-authors include Samuel W. Boellner, Joseph Biederman, Frank A. López, C. Thomas Gualtieri, Philip Beineke, Steven Blotner, David S. Lee, Somnath Sarkar, Donald A. Berry and Michael Elashoff and has published in prestigious journals such as Journal of Clinical Oncology, PEDIATRICS and Brain Injury.

In The Last Decade

Mark C. Chandler

6 papers receiving 352 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark C. Chandler United States	6	188	151	132	81	70	7	382
Glenn M. Seliger United States	7	69 0.4×	131 0.9×	205 1.6×	43 0.5×	37 0.5×	10	350
Béatrice Lemesle France	9	181 1.0×	92 0.6×	50 0.4×	41 0.5×	204 2.9×	17	385
Hendrik Niemann Germany	6	86 0.5×	140 0.9×	71 0.5×	50 0.6×	132 1.9×	16	319
Rocío Sánchez-Carrión Spain	11	71 0.4×	212 1.4×	173 1.3×	57 0.7×	124 1.8×	30	384
Jeff Schaffert United States	10	69 0.4×	170 1.1×	153 1.2×	86 1.1×	23 0.3×	33	334
Nicolas Lejeune Belgium	12	89 0.5×	303 2.0×	175 1.3×	142 1.8×	100 1.4×	39	440
Zarabeth L. Golden United States	7	65 0.3×	72 0.5×	64 0.5×	36 0.4×	46 0.7×	9	200
Laury Chamelian Canada	7	82 0.4×	289 1.9×	237 1.8×	147 1.8×	19 0.3×	12	481
María del Rosario Domínguez-Morales Spain	7	69 0.4×	155 1.0×	131 1.0×	55 0.7×	77 1.1×	8	324
Bonnie M. Scott United States	10	114 0.6×	61 0.4×	113 0.9×	12 0.1×	61 0.9×	23	317

Countries citing papers authored by Mark C. Chandler

Since Specialization

Citations

This map shows the geographic impact of Mark C. Chandler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Chandler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Chandler more than expected).

Fields of papers citing papers by Mark C. Chandler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Chandler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Chandler. The network helps show where Mark C. Chandler may publish in the future.

Co-authorship network of co-authors of Mark C. Chandler

This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Chandler. A scholar is included among the top collaborators of Mark C. Chandler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Chandler. Mark C. Chandler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Chandler, Mark C.. (2022). More on neurotransmitters. 21(9).

2.

Chandler, Mark C., Barbara Elashoff, Andrea Stern Ferris, et al.. (2019). Non-small cell lung cancer (NSCLC) case study examining whether results in a randomized control arm are replicated by a synthetic control arm (SCA).. Journal of Clinical Oncology. 37(15_suppl). 9108–9108. 5 indexed citations

3.

Berry, Donald A., Michael Elashoff, Steven Blotner, et al.. (2017). Creating a synthetic control arm from previous clinical trials: Application to establishing early end points as indicators of overall survival in acute myeloid leukemia (AML).. Journal of Clinical Oncology. 35(15_suppl). 7021–7021. 12 indexed citations

4.

Biederman, Joseph, Frank A. López, Samuel W. Boellner, & Mark C. Chandler. (2002). A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SLI381 (Adderall XR) in Children With Attention-Deficit/Hyperactivity Disorder. PEDIATRICS. 110(2). 258–266. 149 indexed citations

5.

Chandler, Mark C., et al.. (1989). Amantadine. Clinical Neuropharmacology. 12(4). 258–270. 67 indexed citations

6.

Chandler, Mark C., et al.. (1989). Amantadine: a new clinical profile for traumatic brain injury.. PubMed. 12(4). 258–70. 84 indexed citations

7.

Chandler, Mark C., et al.. (1988). Amantadine for the agitated head-injury patient. Brain Injury. 2(4). 309–311. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact